|
Synonyms: CAM-3001 | KPL-301
Compound class:
Antibody
Comment: Mavrilimumab targets CSF2RA (aka GM-CSFRα).
Peptide sequences for this antibody are available from its IMGT/mAb-DB record. Peptide sequence analysis identifies mavrilimumab as antibody 6 in patent US8263075 [2]. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Burmester GR, McInnes IB, Kremer JM, Miranda P, Vencovský J, Godwood A, Albulescu M, Michaels MA, Guo X, Close D et al.. (2018)
Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor α Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis. Arthritis Rheumatol, 70 (5): 679-689. [PMID:29361199] |
|
2. Cohen ES, Minter RR, Harrison PR, Sleeman MA, Nash AD, Fabri LJ. (2012)
Antibody molecule for human GM-CSF receptor alpha. Patent number: US8263075. Assignee: Medimmune Limited. Priority date: 27/03/2006. Publication date: 11/09/2012. |
|
3. Kiniksa Pharmaceuticals.
Mavrilimumab. Accessed on 04/03/2020. Modified on 04/03/2020. kiniksa.com, https://www.kiniksa.com/our-pipeline/mavrilimumab/ |
|
4. Nair JR, Edwards SW, Moots RJ. (2012)
Mavrilimumab, a human monoclonal GM-CSF receptor-α antibody for the management of rheumatoid arthritis: a novel approach to therapy. Expert Opin Biol Ther, 12 (12): 1661-8. [PMID:23094973] |
